Avalyn Pharma
AVLN
Avalyn Pharma (AVLN) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Raymond James | Initiated Coverage | Outperform | $60.00 | Oct 2, 2026 |
| Morgan Stanley | Maintained | Overweight | $57.00 from $53.00 | Aug 13, 2026 |
| Guggenheim | Initiated Coverage | Buy | $80.00 | May 26, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $51.00 | May 26, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $53.00 | May 26, 2026 |
Frequently asked questions
What is the latest analyst rating on AVLN?
On Oct 2, 2026, Raymond James initiated coverage of Avalyn Pharma at Outperform with a price target of $60.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.